JA
Josh Arnold Investment Consultant, LLC
13F filer · CIK 0001911348Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$159MU.S. long equity reported on 13F
Positions2011 new · 4 closed
Net flow last quarter+$23.1MBuys minus sells
Top 10 positions weight94.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202620 positions | |||||
| $88.9M | 55.94% | 0.00% | -1.3% | Q4 2021 | |
| $21.7M | 13.67% | 0.00% | +3.6% | Q4 2021 | |
| $13.4M | 8.42% | 2.45% | Not reported | Q4 2022 | |
| $7.82M | 4.92% | 0.43% | New | Q2 2026 | |
| $5.7M | 3.59% | 0.30% | New | Q2 2026 | |
| $3.86M | 2.43% | 4.06% | New | Q2 2026 | |
| $2.42M | 1.52% | 0.00% | New | Q2 2026 | |
| $2.38M | 1.50% | Not reported | New | Q2 2026 | |
| $2.02M | 1.27% | 0.25% | New | Q2 2026 | |
| $1.74M | 1.09% | 0.00% | -29.1% | Q4 2024 | |
| $1.56M | 0.98% | 0.01% | +13.0% | Q1 2026 | |
| $1.5M | 0.95% | Not reported | -53.1% | Q3 2023 | |
| $1.02M | 0.64% | 4.13% | New | Q2 2026 | |
| $972K | 0.61% | 0.00% | Not reported | Q4 2024 | |
| $811K | 0.51% | 0.02% | New | Q2 2026 | |
| $770K | 0.48% | Not reported | Not reported | Q3 2022 | |
| $462K | 0.29% | Not reported | Not reported | Q4 2021 | |
| $370K | 0.23% | Not reported | Not reported | Q2 2023 | |
| $363K | 0.23% | 0.00% | Not reported | Q3 2025 | |
| $257K | 0.16% | 0.00% | Not reported | Q2 2025 | |
| Q1 2026Reported May 15, 202613 positions | |||||
| $79M | 67.54% | 0.00% | -1.5% | Q4 2021 | |
| $18.3M | 15.67% | 0.00% | -11.1% | Q4 2021 | |
| $7.57M | 6.47% | 2.47% | +0.2% | Q4 2022 | |
| $3.21M | 2.74% | Not reported | -22.6% | Q3 2023 | |
| $3.08M | 2.63% | 0.00% | -17.4% | Q4 2024 | |
| $1.91M | 1.63% | 0.01% | +7.7% | Q1 2025 | |
| $1.35M | 1.16% | 0.01% | New | Q1 2026 | |
| $673K | 0.58% | 0.02% | New | Q1 2026 | |
| $460K | 0.39% | 0.00% | Not reported | Q4 2024 | |
| $448K | 0.38% | 0.00% | Not reported | Q3 2025 | |
| $355K | 0.30% | Not reported | -11.9% | Q2 2023 | |
| $321K | 0.27% | 0.00% | Not reported | Q3 2025 | |
| $280K | 0.24% | 0.00% | -7.1% | Q4 2025 | |
| Q4 2025Reported Feb 20, 202615 positions | |||||
| $86M | 64.14% | 0.00% | -3.7% | Q4 2021 | |
| $22.8M | 17.04% | 0.00% | -13.0% | Q4 2021 | |
| $8.76M | 6.53% | 2.49% | +1104.3% | Q4 2022 | |
| $4.52M | 3.37% | 0.00% | +26.1% | Q4 2024 | |
| $4.3M | 3.21% | Not reported | -31.7% | Q3 2023 | |
| $1.77M | 1.32% | 0.60% | New | Q4 2025 | |
| $1.66M | 1.24% | 0.00% | -23.4% | Q1 2025 | |
| $1.58M | 1.18% | 0.00% | New | Q4 2025 | |
| $767K | 0.57% | 0.02% | New | Q4 2025 | |
| $429K | 0.32% | Not reported | -8.5% | Q4 2021 | |
| $422K | 0.31% | Not reported | Not reported | Q2 2023 | |
| $346K | 0.26% | 0.00% | Not reported | Q4 2024 | |
| $329K | 0.25% | 0.00% | New | Q4 2025 | |
| $310K | 0.23% | 0.00% | Not reported | Q3 2025 | |
| ATADAPYAdaptimmune Therapeutics PLC | $37.8K | 0.03% | 0.00% | New | Q4 2025 |
| Q3 2025Reported Nov 14, 202513 positions | |||||
| $83.6M | 67.36% | 0.00% | -50.5% | Q4 2021 | |
| $25M | 20.12% | 0.00% | -49.7% | Q4 2021 | |
| $6.08M | 4.90% | Not reported | -40.5% | Q3 2023 | |
| $3.68M | 2.96% | 0.00% | -58.0% | Q4 2024 | |
| $2.48M | 2.00% | 0.01% | -58.6% | Q1 2025 | |
| $713K | 0.57% | 0.21% | -92.5% | Q4 2022 | |
| $619K | 0.50% | 0.00% | New | Q3 2025 | |
| $512K | 0.41% | Not reported | -51.2% | Q4 2021 | |
| $429K | 0.35% | 2270.00% | New | Q3 2025 | |
| $275K | 0.22% | 0.00% | -15.7% | Q4 2024 | |
| $261K | 0.21% | 0.00% | Not reported | Q2 2023 | |
| $256K | 0.21% | 0.00% | New | Q3 2025 | |
| $239K | 0.19% | 0.01% | -50.0% | Q2 2025 | |
Premium opens every quarter this fund has filed